Stock Track | Krystal Biotech Inc. (KRYS) Soars 5.02% in Pre-Market on Positive Earnings and Analyst Outlook

Stock Track

02-20

Krystal Biotech Inc. (KRYS) witnessed a pre-market soar of 5.02% on Thursday, February 20, 2025, driven by robust financial results and an optimistic analyst outlook.

The company reported stellar earnings for the fourth quarter and full year 2024, reflecting the successful launch of its flagship product, VYJUVEK, for the treatment of dystrophic epidermolysis bullosa (DEB). Krystal Biotech achieved net income per share of $3.12 for 2024, up from $0.40 in the previous year, marking six straight quarters of positive earnings and four consecutive quarters of sequential growth.

Furthermore, net VYJUVEK revenue for Q4 2024 stood at $91.1 million, contributing to a total revenue of $290.5 million for the year. The company maintained a robust gross margin of 95% in Q4 2024, showcasing its operational efficiency and strong financial position with $749.6 million in total cash and investments.

In addition to the impressive financial performance, Citi analyst Yigal Nochomovitz raised the firm's price target on Krystal Biotech to $215 from $206, while maintaining a Neutral rating. Nochomovitz's positive outlook, coupled with the company's strong earnings and revenue growth, fueled investor confidence, driving the stock's pre-market surge.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1109480944"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1109480944\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1109480944?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-20 22:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1109480944","market":"hk","top_or_hot":-1,"title":"Stock Track | Krystal Biotech Inc. (KRYS) Soars 5.02% in Pre-Market on Positive Earnings and Analyst Outlook","media":"Stock Track","content":"<p>Krystal Biotech Inc. (KRYS) witnessed a pre-market soar of 5.02% on Thursday, February 20, 2025, driven by robust financial results and an optimistic analyst outlook.</p>\n\n<p>The company reported stellar earnings for the fourth quarter and full year 2024, reflecting the successful launch of its flagship product, VYJUVEK, for the treatment of dystrophic epidermolysis bullosa (DEB). Krystal Biotech achieved net income per share of $3.12 for 2024, up from $0.40 in the previous year, marking six straight quarters of positive earnings and four consecutive quarters of sequential growth.</p>\n\n<p>Furthermore, net VYJUVEK revenue for Q4 2024 stood at $91.1 million, contributing to a total revenue of $290.5 million for the year. The company maintained a robust gross margin of 95% in Q4 2024, showcasing its operational efficiency and strong financial position with $749.6 million in total cash and investments.</p>\n\n<p>In addition to the impressive financial performance, Citi analyst Yigal Nochomovitz raised the firm's price target on Krystal Biotech to $215 from $206, while maintaining a Neutral rating. Nochomovitz's positive outlook, coupled with the company's strong earnings and revenue growth, fueled investor confidence, driving the stock's pre-market surge.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Krystal Biotech Inc. (KRYS) Soars 5.02% in Pre-Market on Positive Earnings and Analyst Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Krystal Biotech Inc. (KRYS) Soars 5.02% in Pre-Market on Positive Earnings and Analyst Outlook\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2025-02-20 22:29</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Krystal Biotech Inc. (KRYS) witnessed a pre-market soar of 5.02% on Thursday, February 20, 2025, driven by robust financial results and an optimistic analyst outlook.</p>\n\n<p>The company reported stellar earnings for the fourth quarter and full year 2024, reflecting the successful launch of its flagship product, VYJUVEK, for the treatment of dystrophic epidermolysis bullosa (DEB). Krystal Biotech achieved net income per share of $3.12 for 2024, up from $0.40 in the previous year, marking six straight quarters of positive earnings and four consecutive quarters of sequential growth.</p>\n\n<p>Furthermore, net VYJUVEK revenue for Q4 2024 stood at $91.1 million, contributing to a total revenue of $290.5 million for the year. The company maintained a robust gross margin of 95% in Q4 2024, showcasing its operational efficiency and strong financial position with $749.6 million in total cash and investments.</p>\n\n<p>In addition to the impressive financial performance, Citi analyst Yigal Nochomovitz raised the firm's price target on Krystal Biotech to $215 from $206, while maintaining a Neutral rating. Nochomovitz's positive outlook, coupled with the company's strong earnings and revenue growth, fueled investor confidence, driving the stock's pre-market surge.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KRYS","symbol_name":"Krystal Biotech Inc.","start_time":0,"source_url":"","article_id":"1109480944","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1109480944","pubTimestamp":1740061740,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Krystal Biotech Inc.  witnessed a pre-market soar of 5.02% on Thursday, February 20, 2025, driven by robust financial results and an optimistic analyst outlook.The company reported stellar earnings for the fourth quarter and full year 2024, reflecting the successful launch of its flagship product, VYJUVEK, for the treatment of dystrophic epidermolysis bullosa . Krystal Biotech achieved net income per share of $3.12 for 2024, up from $0.40 in the previous year, marking six straight quarters of po","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KRYS":"Krystal Biotech Inc."},"translate_title":"股票轨迹Krystal Biotech Inc.(KRYS)因积极的盈利和分析师前景而盘前飙升5.02%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KRYS":1},"content_text":"Krystal Biotech Inc. (KRYS) witnessed a pre-market soar of 5.02% on Thursday, February 20, 2025, driven by robust financial results and an optimistic analyst outlook.\nThe company reported stellar earnings for the fourth quarter and full year 2024, reflecting the successful launch of its flagship product, VYJUVEK, for the treatment of dystrophic epidermolysis bullosa (DEB). Krystal Biotech achieved net income per share of $3.12 for 2024, up from $0.40 in the previous year, marking six straight quarters of positive earnings and four consecutive quarters of sequential growth.\nFurthermore, net VYJUVEK revenue for Q4 2024 stood at $91.1 million, contributing to a total revenue of $290.5 million for the year. The company maintained a robust gross margin of 95% in Q4 2024, showcasing its operational efficiency and strong financial position with $749.6 million in total cash and investments.\nIn addition to the impressive financial performance, Citi analyst Yigal Nochomovitz raised the firm's price target on Krystal Biotech to $215 from $206, while maintaining a Neutral rating. Nochomovitz's positive outlook, coupled with the company's strong earnings and revenue growth, fueled investor confidence, driving the stock's pre-market surge.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}